Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autovaccines vs suppressive antibiotics in hip or knee prosthesis infections
2024-520226-10-00Phase 3Authorised
- Sponsor
- IDIVAL
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of autologous bacterial vaccine in periprosthetic joint infection (PJI) (2 arms), sponsored by IDIVAL. Primary endpoint: Clinical course of prosthetic joint infection. Planned start Jan 2025; status: authorised.
02
Drugs
autologous bacterial vaccine
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2024-520226-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520226-10-00.